Date: 2017-02-23
Type of information: Nomination
Compound: chief operating officer
Company: Celgene (USA - NJ)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 23, 2017, Celgene announced that President and Chief Operating Officer Jackie Fouse has decided to retire from Celgene effective June 30, 2017 . She will continue to serve as President and COO until April 1 , and through June 30 , she will serve as a strategic advisor to the management team. Jackie will not stand for reelection to the Celgene Board of Directors at the upcoming Annual Meeting in June. She joined Celgene in 2010 as Chief Financial Officer. In 2014, she was appointed President of Celgene's Hematology & Oncology Franchise and in 2016 she was promoted to President and COO.
- The company also announced the promotion of Scott Smith to President and COO, effective April 1, 2017 , and the promotion of Terrie Curran to President, Global Inflammation & Immunology (I&I) Franchise, effective April 1, 2017 . Scott Smith joined Celgene in 2008 and successfully built and launched Celgene's I&I Franchise. Before joining Celgene , Scott served as Global Commercial Head for Biovail .
Terrie Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and established the framework and built the capabilities for the successful U.S. launch of Otezla®. In early 2016, Terrie was promoted to Head of Worldwide Commercial Markets for the I&I Franchise and is leading the worldwide launch of OTEZLA®. Prior to joining Celgene , Terrie was a Senior Vice President at Merck&co , where she led the Global Women's Health franchise from 2009-2013.
Financial terms:
Latest news:
Is general: Yes
